Skip to main content

Table 2 Number of novel components of the human exosome targeted by the serum of patients with idiopathic inflammatory myopathy (IIM), scleroderma, or the polymyositis/scleroderma (PM/Scl) overlap syndrome

From: Autoantibodies directed to novel components of the PM/Scl complex, the human exosome

   Number of targeted components per seruma
Number of reactive serab   1 2 3 4 5 6
IIM (n = 48) 30 16 8 3 1 1 1
Scleroderma (n = 11) 8 5 3 0 0 0 0
Myositis/scleroderma overlap (n = 10) 6 4 1 1 0 0 0
  1. aFor these calculations, only the novel exosome components (hRrp4p, hRrp40p, hRrp41p, hRrp42p, hRrp46p, and hCsl4p) were taken into account. bTotal number of sera reactive with at least one of the novel components analyzed.